Authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19
16/09/2021 – AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
16/09/2021 – AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)